Skin patch T-cell Covid vaccine to be trialled in Switzerland
The new vaccine will be administered as a tiny skin patch bristling with micro-needles that release the shot within seconds.
Keystone / Alexandra Wey
A British biotech firm is set to start clinical trials in Switzerland of a skin patch vaccine against Covid-19 that uses T-cells and could offer longer-lasting immunity than existing vaccines.
This content was published on
2 minutes
The Guardian/swissinfo/sb
Español
es
Suiza someterá a prueba vacuna COVID en parche cutáneo
Emergex announcedExternal link on Monday that it had received the green light from the Swiss drugs regulator to carry out initial human trials in Lausanne, starting January 3, 2022.
The company’s easy-to-administer skin patch vaccine primes T-cells – a group of immune cells that can target and destroy virus-infected cells – to remove infected cells from the body quickly after infection, thus preventing viral replication and disease.
Robin Cohen, Emergex’s chief commercial officer, told The GuardianExternal link newspaper: “This is the first time a regulator has approved a Covid vaccine to go into clinical trials whose sole purpose is to generate a targeted T-cell response in the absence of an antibody response and those T-cells look for infected cells and kill them.”
Current Covid-19 vaccines mainly generate an antibody response that wanes over time, which means people need booster shots to maintain protection against the virus. The Emergex vaccine works differently, by killing infected cells quickly. This means it could offer longer-lasting immunity – possibly for decades – and could also be better at fighting virus mutations, said Cohen.
The trial will be conducted by Blaise Genton, a professor at the University of Lausanne’s centre for primary care and public health. He said: “This exciting new scientific approach to developing a vaccine against Sars-CoV-2 addresses the need to generate a T-cell response to elicit long-term immunity.”
In all, 26 people will receive a high and a low dose of its experimental Covid-19 vaccine. Interim results from the trial are expected in June.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Rhine could warm by up to 4°C by 2100, scientists warn
This content was published on
The water temperature of the Rhine River could rise by up to 4.2° degrees Celsius by the end of the century due to the warming planet, scientists warn.
This content was published on
The Federal Council wants to explore the possibilities of joining the European Union’s €800-billion rearmament programme without compromising Swiss neutrality.
Defence Minister Pfister stresses importance of Swiss mission in Balkans
This content was published on
During a visit to the Balkans region last week, Swiss Defence Minister Martin Pfister met Swisscoy peacekeeping troops in Kosovo.
Premiere for Swiss Air Force on French National Day
This content was published on
On July 14, the Swiss Air Force will take part in the traditional air parade in Paris to mark the French bank holidays with an F/A-18 fighter jet. This is a first for Switzerland.
Swiss launch competition for memorial to Nazi victims
This content was published on
The victims of Nazi Germany are to be commemorated on the Casinoterrasse in Bern. A competition will be held to determine what the site will look like.
This content was published on
The cantonal police of Graubünden in eastern Switzerland have arrested and convicted five cocaine dealers in Chur within a week.
This content was published on
The Swiss business umbrella organisation Economiesuisse and the employers' association broadly support the package of agreements negotiated with the European Union.
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Vaccine alternative has limited impact on Covid campaign
This content was published on
The offer of a non-mRNA Covid vaccine in Switzerland has failed to speed up the government’s vaccination campaign, experts say.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.